Process and Formulation Analysis*

  • Process and Formu­la­tion Analyt­ical Methods Development
  • Drug Substance HPLC Purity Profiling, Stability Indi­cating Method Development
  • Method Vali­da­tion under GLP per FDA-CDER and ICH Regu­la­tions and Guidelines
  • QA Phase Inspec­tions and Data Review
  • DS and Drug Product (DP) Impu­rity Iden­ti­fi­ca­tion and Characterization
  • Stability Studies for DS/API (12 – 24M)
  • Drug Substance (DS) and Drug Product (DP) Impu­rity Iden­ti­fi­ca­tion and Characterization
  • GC Residual Solvent Analysis
  • Issuance of Certifi­cate of Analysis (COA)
  • DP HPLC Purity Profiling, Stability Indi­cating and Assay Method Development

Bioanalysis Studies*

  • LC/MS and CE/MS method development
  • Method vali­da­tion for drugs/​metabolites per FDA or ICH
  • Quan­ti­ta­tive bioanalysis of preclin­ical and early clin­ical samples
  • COA and recer­ti­fi­ca­tion for test substances, refer­ence and metabo­lite standards
  • Metabo­lite profiling for cold and C‑14 labeled compounds, ID and characterization
  • Metabo­lite isolation/​enrichment by frac­tion collec­tion, prep and/​or semi-prep columns
  • Quan­ti­ta­tion of test article and metabolites
services preclinical pharmaceutical capabilities metabolism DSC 6788.

Metabolism Studies*

  • in-vivo analyt­ical ADME services and in-life phase through a part­nering company
  • in-vivo study types include mass balance, tissue distri­b­u­tion, metabo­lite profiling / radio profiling and ID, discovery PK, formu­la­tion bioavail­ability screening and cassette PK
  • in-vitro metab­o­lism studies with pooled liver micro­somes, hepa­to­cytes and S9 fraction
  • Inter­species compar­isons in mouse, rat, dog, rabbit, pig, monkey and human
  • P450 isozyme phenotyping

Other Services*

  • Non-Clin­ical Phar­ma­co­log­ical and Toxi­co­log­ical studies
  • Dissolved O2 Analysis in DP
  • Large-scale Synthesis Support at Manu­fac­turing Sites
  • Devel­oping DS and DP Specifications
  • Product Chem­istry (i.e. physical/​chemical chrac­ter­i­za­tion, storage stability analysis, etc.)

Pharmaceutical aNDA Capabilities for Oncological Agents*

  • USP methods Transfer and Validation
  • Formu­la­tions Development
  • Formu­la­tion Stability Studies
  • Spec­i­fi­ca­tion
  • Drug Substance and Drug Product Manu­fac­turing Support


All GC related analysis are outsourced to other Tentamus GLP labs.

We Value Your Privacy
We use cookies on our website. Some of them are essential, while others help us to improve this website and your experience.
Privacy Settings
Customer Interaction
These technologies will allow you to contact us through our website, i.e. use the chat widget.
Name LiveChat
Provider LiveChat Software S.A., ul. Zwycięska 47, 53-033 Wroclaw, Poland
Purpose Communication with clients via online chat using the API of the chat service LiveChat.
Privacy Policy
Cookie Name __lc_cid, __lc_cst
Cookie Expiry 2 years
Technologies required to enable the core functionality of this website.
Name Cookie Consent
Provider Owner of this website, Imprint
Purpose Saves the visitors preferences selected in the cookie banner.
Cookie Name ws_cookie_consent
Cookie Expiry 1 year